The fibre evidence points at 25 to 29 grams a day. A supplement is not the same thing.

The number with the most evidence behind it is 25 to 29 grams of fibre a day. A series of systematic reviews and meta-analyses published in The Lancet in 2019, drawing on just under 135 million person-years of data from 185 prospective studies and 58 clinical trials in 4,635 adults, found that risk reduction across a range of critical outcomes was greatest when daily dietary fibre intake fell between 25 g and 29 g [s1]. What that evidence does not support is the substitution most people reach for: the trials of isolated fibre supplements produce far smaller effects, on far narrower outcomes, than the observational data on fibre-rich diets suggest.

What the observational data show

Comparing the highest consumers of dietary fibre with the lowest, the observational component of the Lancet series found a 15–30% decrease in all-cause and cardiovascular mortality, and in the incidence of coronary heart disease, stroke incidence and mortality, type 2 diabetes and colorectal cancer [s1]. Dose-response curves suggested intakes above 29 g could confer still greater protection against cardiovascular disease, type 2 diabetes, and colorectal and breast cancer [s1]. Similar findings held for whole-grain intake [s1].

The trial component of the same series is more modest but consistent in direction: clinical trials showed significantly lower body weight, systolic blood pressure and total cholesterol at higher versus lower fibre intakes [s1].

Two features of the series are worth holding onto. First, glycaemic index and glycaemic load — the carbohydrate metrics that dominate consumer nutrition discourse — performed markedly worse. Smaller or no risk reductions appeared in the observational data when comparing diets characterised by low rather than higher glycaemic index or load [s1]. Second, the authors graded their own certainty: moderate for dietary fibre, low to moderate for whole grains, and low to very low for glycaemic index and load [s1]. Moderate certainty is a real qualifier, not a formality.

What supplement trials find instead

A 2025 meta-analysis pooled 34 randomised trials in 1,804 adults with overweight or obesity, testing fibre supplementation at 1.5 to 40 g a day for 3 to 16 weeks against placebo, without energy restriction [s2]. Across all trials, supplementation significantly reduced glycated haemoglobin by 0.13%, fasting insulin by 0.82 µIU/mL and HOMA-IR insulin resistance by 0.33 [s2].

Those are small effects on intermediate markers, over weeks, in a specific population. Subgroup analyses by fibre type produced inconsistent and occasionally unwelcome results — one subgroup showed a 2.85 kg decrease in body weight alongside a 9.03 mg/dL increase in LDL cholesterol, and a mixed subgroup showed systolic blood pressure rising by 3.85 mmHg [s2]. The review's own conclusion is that different fibre specificities may have distinct effects and that gut microbiota composition and individual health goals should inform any choice [s2] — which is a way of saying the category does not behave as one thing.

The commonest reason people take fibre, tested

For chronic constipation in older adults, the evidence is thinner than the practice. A 2025 meta-analysis found seven randomised trials involving 187 participants in total [s3]. Fibre supplementation produced no significant improvement in stool frequency (standardised mean difference 0.25, 95% CI −0.488 to 0.988, P = 0.507) [s3]. It did significantly reduce the frequency of laxative or enema use (SMD −1.224, −1.786 to −0.662) and increase faecal bifidobacteria concentrations (SMD 5.142, 3.716 to 6.568) [s3]. The reviewers call for more robust trials to determine effective dosage and duration [s3].

A null on the outcome people care about, alongside a significant result on a related one, across 187 people, is not a settled answer in either direction.

Why the two literatures may not be measuring the same thing

The observational fibre signal is a signal about diets, not about a molecule. People eating 29 g of fibre a day are eating substantially different food from people eating 15 g, and the Lancet authors present their findings as being about carbohydrate quality — fibre and whole grains together — rather than about a nutrient that could be added back to an otherwise unchanged diet [s1]. That the isolated supplement trials produce much weaker effects is what would be expected if the food, not the fibre alone, is doing the work — though it is equally consistent with the supplement trials being too short and too small to detect a real effect.

The honest position is that the target intake has moderate-certainty observational support and supportive short-term trial data on risk factors [s1], and that the evidence supporting a fibre supplement as a substitute for that intake is weak, inconsistent, and confined to intermediate outcomes over weeks [s2] [s3].

This article is informational and is not medical advice. Increasing fibre intake is a clinical question for anyone with inflammatory bowel disease, a history of bowel obstruction, or a diagnosed motility disorder.

Sources

• Carbohydrate quality and human health: a series of systematic reviews and meta-analyses — The Lancet, 2019
• Effects of Supplementation With Different Specificities of Dietary Fiber on Health-Related Indicators in Adults With Overweight or Obesity — Nutrition Reviews, 2025-01-16
• Effects of Dietary Fiber Supplementation on Chronic Constipation in the Elderly: A Systematic Review and Meta-Analysis of Randomized Controlled Trials — Foods, 2025-06-30